Tests radiation that spares nerves and blood vessels for erections in prostate cancer
Tests a radiation method sparing erection nerves in men with early prostate cancer.
Plain-language title generated from the registry record
Registry title: EREctile Function Preservation for Prostate Cancer Radiation Therapy (ERECT)
Key facts
- Where
- Utrecht, NetherlandsSee the site
Where in Netherlands
- University Medical Center UtrechtUtrecht, NetherlandsTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- UMC Utrecht
- Trial code
- NCT04861194
- Record updated
- 5 March 2026
- Original description
Single-arm phase II trial of 70 men with low- or intermediate-risk prostate cancer receiving magnetic resonance guided adaptive radiotherapy (MRgRT) in 5 fractions of 7.25 Gy, additionally sparing the neurovascular bundles, the internal pudendal arteries, the corpora cavernosa, and the penile bulb for erectile function preservation.Read full original descriptionShow less
EREctile Function Preservation for Prostate Cancer Radiation Therapy (ERECT); a Prospective Phase II Trial
Single-arm phase II trial of 70 men with low- or intermediate-risk prostate cancer receiving magnetic resonance guided adaptive radiotherapy (MRgRT) in 5 fractions of 7.25 Gy, additionally sparing the neurovascular bundles, the internal pudendal arteries, the corpora cavernosa, and the penile bulb for erectile function preservation.
Inclusion: Age ≥18 years; Histologically proven adenocarcinoma of the prostate; Low-risk or intermediate-risk prostate cancer according to NCCN risk categories (low risk: T1c-T2a, Gleason score ≤6, and PSA <10 µg/L; intermediate risk: T2b-T2c or Gleason score 7 or PSA 10-20 µg/L); Patients with pT1a/b tumor diagnosis after transurethral resection of the prostate (TURP); Domain score of 17-25 on the International Index of Erectile Function-5 (IIEF-5) questionnaire; Karnofsky score of 70-100; Written informed consent.
Exclusion: Use of (neo-)adjuvant androgen deprivation therapy; Previous pelvic irradiation or radical prostatectomy; Clinical evidence of metastatic disease; High-risk prostate cancer according to NCCN risk categories (T3a or Gleason score 8-10 or PSA >20 µg/L); Patients with "bulky" iT3 tumor diagnosis; Patients who are unable to undergo MRI; Patients who are incompetent to sign written informed consent.